UX053
UX053-CL101
Phase 2 mab terminated
Quick answer
UX053 for Glycogen Storage Disease Type III is a Phase 2 program (mab) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Glycogen Storage Disease Type III
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated